Comparative Pharmacology
Head-to-head clinical analysis: LARIN FE 1 5 30 versus LO OVRAL 28.
Head-to-head clinical analysis: LARIN FE 1 5 30 versus LO OVRAL 28.
LARIN FE 1.5/30 vs LO/OVRAL-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration; alters endometrial receptivity. Norethindrone also decreases ovarian estrogen production.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
None Documented
None Documented
Ethinyl estradiol terminal half-life is approximately 13-17 hours; norethindrone terminal half-life is approximately 7-10 hours. Steady-state is reached within 5-10 days.
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Ethinyl estradiol and norethindrone are primarily excreted via renal (urine) and fecal routes. Approximately 40-50% of ethinyl estradiol is excreted renally as metabolites, with 20-30% in feces. Norethindrone metabolites are excreted ~50-70% renally and 20-30% fecally. Less than 5% is excreted unchanged.
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive